The strategic deployment of deployment advances the cash model and the development initiatives of the company’s blockchain
Sarasota, FL, September 16, 2025 (Globe Newswire)-Silo Pharma, Inc. (Nasdaq: Silo) (“Silo” or “Company”), a diversified biopharmaceutical and cryptocurrency company, announced its first purchases of Crypto-Tresor Crypto-Tresor strategy.
The acquisition by the Ethereum (ETH) and Solana (Sol) token company marks the first step towards the integration of the cryptocurrency in its cash titles and lays the foundations for wider tokenization initiatives of blockchain and real assets (RWA). The investment highlights the company’s belief in the long-term value of digital assets and the potential of underlying blockchain technology to shape the future of biotechnology.
“Our first purchases from Ethereum and Solana reflect our deep conviction in decentralized blockchain and decentralized finance as the main intelligent contract platforms,” said Eric Weisblum, CEO of Silo. “We have started to mark the tokens for the generation of income and the appreciation of capital to further strengthen our financial situation and support the clinical progression of our biopharmaceutical assets.”
The complete strategy of digital assets of Silo is aligned with the adoption of acceleration of digital assets by institutional investors and global companies, supported by a regulatory landscape which evolves regularly to allow greater acceptance of the
About Silo Pharma
Silo Pharma is a biopharmaceutical and diversified cryptocurrency cash company. His therapeutic accent aims to deal with poorly served conditions, including psychiatric disorders induced by stress, chronic pain and diseases of the central nervous system (SNC). The company’s portfolio includes innovative programs such as SPC-15 for SSPT, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is carried out in collaboration with the main universities and laboratories. Silopharma.com
Prospective declarations
This press release contains “prospective declarations” within the meaning of the “Safe Harbor” provisions of the 1995 law on private security disputes. Such declarations imply risks, uncertainties and other known and unknown factors which could ensure that the real results of Silo Pharma, Inc. (“silo” or “the company”) differ considerably from the results expressed or involved by these declarations, including the changes in early sources of income, future economic and competitive conditions, difficulties in the development of technological platforms the company, retention and extent products and other factors. Consequently, although the company considers that the expectations reflected in such prospective declarations are reasonable, there is no guarantee that such expectations will prove to be correct. The company declines any obligation to update or publicly publish any revision of the prospective information contained in this press release, whether following new information, future events, or otherwise, after the date of this press release or reflect the occurrence of unforeseen events, except according to the law.
Contact
800-705-0120
(Protected by e-mail)
